Sustained gallbladder stasis promotes cholesterol gallstone formation in the ground squirrel

被引:13
|
作者
Xu, QW [1 ]
Mantle, M [1 ]
Pauletzki, JG [1 ]
Shaffer, EA [1 ]
机构
[1] UNIV CALGARY,FAC MED,DEPT MED,GI RES GRP,CALGARY,AB,CANADA
关键词
D O I
10.1053/jhep.1997.v26.pm0009328300
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although gallbladder stasis exists in most patients with cholesterol gallstones, it is unknown whether stasis is a causative factor of gallstone disease or merely a consequence of it, We studied the impact of sustained gallbladder stasis induced by a cholecystokinin (CCK)-A receptor antagonist (MK-329) on gallstone formation in ground squirrels fed either a trace or a high-cholesterol diet. MK-329 markedly inhibited gallbladder contraction in vitro in response to CCK (at EC100, control: 3.6 +/- 0.5 vs. MK-329: 1.1 +/- 0.3 g; P < .05) and increased gallbladder fasting volume in vivo (control: 462 +/- 66 vs. MK-329: 1,004 +/- 121 mu L; P < .05). Whereas the high-cholesterol diet alone (1%-cholesterol diet + placebo) increased the cholesterol saturation index (CSI) in control animals (trace-cholesterol diet + placebo), MK-329 significantly (P < .05) decreased the CSI in both hepatic and gallbladder bile in animals on the trace-(trace-cholesterol diet + MK-329) as well as on the high-cholesterol diets (1%-cholesterol diet + MK-329), The mucin content of the mucus layer on the epithelial surface of the gallbladder wall more than doubled (P < .05) with the high-cholesterol diet; adding MK-329 to the latter group produced a further 82% increase (P < .05). The cholesterol diet + MK-329 group had the highest (100%) incidence of cholesterol crystals that were evident in fresh gallbladder bile, coincident with a shortened nucleation time (2.5 +/- 0.6 days; P < .05 vs, the cholesterol diet + placebo group, 5.8 +/- 1.0 days or the other 2 groups, > 21 days), Bile from animals on the trace-cholesterol diet, whether or not receiving MK-329, lacked crystals in bile and exhibited a normal nucleation time (> 21 days). Thus, stasis pw se may lower the CSI, but its detrimental effect on the gallbladder predominates locally, and so accelerates cholesterol crystal formation in this model.
引用
收藏
页码:831 / 836
页数:6
相关论文
共 50 条
  • [21] Iron deficiency promotes cholesterol gallstone formation.
    Murray, KP
    Shin, JH
    Fox-Talbot, MK
    Johnston, SM
    Lipsett, PA
    Lillemoe, KD
    Pitt, HA
    GASTROENTEROLOGY, 1998, 114 (04) : A1307 - A1307
  • [22] GALLBLADDER AND GALLSTONE FORMATION
    CALDWELL, FT
    LEVITSKY, K
    ANNALS OF SURGERY, 1967, 166 (05) : 753 - &
  • [23] CHOLESTEROL SUPERSATURATED BILE FORMATION IN HEPATOLITHIASIS DIFFERS FROM THAT IN CHOLESTEROL GALLSTONE DISEASE IN THE GALLBLADDER
    SHODA, J
    HE, BF
    YOSHIDA, T
    TANAKA, N
    MATSUZAKI, Y
    OSUGA, T
    GASTROENTEROLOGY, 1994, 106 (04) : A985 - A985
  • [24] CHOLESTEROL GALLSTONE FORMATION IN MAN AND POTENTIAL TREATMENTS OF THE GALLBLADDER MOTILITY DEFECT
    PORTINCASA, P
    STOLK, MFJ
    VANERPECUM, KJ
    PALASCIANO, G
    VANBERGEHENEGOUWEN, GP
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 : 63 - 78
  • [25] The gallbladder: Innocent bystander or major factor in cholesterol-gallstone formation?
    Van Erpecum, KJ
    Wang, DQH
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2005, 146 (04): : 202 - 204
  • [26] ALTERED GALLBLADDER ION-TRANSPORT DURING CHOLESTEROL GALLSTONE FORMATION
    ABDOU, MS
    STRICHARTZ, S
    ABEDIN, M
    PALANT, C
    ROSLYN, JJ
    GASTROENTEROLOGY, 1987, 92 (05) : 1713 - 1713
  • [27] Effect of the prokinetic agent, erythromycin, in the richardson ground squirrel model of cholesterol gallstone disease
    Xu, QW
    Scott, RB
    Tan, DTM
    Shaffer, EA
    HEPATOLOGY, 1998, 28 (03) : 613 - 619
  • [29] ROLE OF GALLBLADDER IN GALLSTONE FORMATION
    NAKAYAMA, F
    VANDERLI.W
    ACTA CHIRURGICA SCANDINAVICA, 1974, 140 (01): : 45 - 49
  • [30] ALTERATIONS IN GALLBLADDER CALCIUM AND PROTEIN-CONCENTRATION DURING CHOLESTEROL GALLSTONE FORMATION
    DOTY, JE
    ROSLYN, JJ
    PITT, HA
    KUCHENBECKER, S
    DENBESTEN, L
    CLINICAL RESEARCH, 1981, 29 (01): : A31 - A31